Qualigen Therapeutics Ownership
| QLGN Stock | USD 4.47 0.31 6.49% |
Shares in Circulation | First Issued 2015-06-30 | Previous Quarter 7.6 M | Current Value 387.9 K | Avarage Shares Outstanding 2.9 M | Quarterly Volatility 4.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Qualigen |
Qualigen Stock Ownership Analysis
The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Qualigen Therapeutics recorded earning per share (EPS) of 3635.0. The entity last dividend was issued on the 26th of May 2020. The firm had 1:50 split on the 5th of November 2024. Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Qualigen Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. To find out more about Qualigen Therapeutics contact Kevin II at 760 452 8111 or learn more at https://www.qlgntx.com.Besides selling stocks to institutional investors, Qualigen Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Qualigen Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Qualigen Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Qualigen Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Qualigen Therapeutics Insider Trades History
Roughly 4.0% of Qualigen Therapeutics are currently held by insiders. Unlike Qualigen Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Qualigen Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Qualigen Therapeutics' insider trades
Qualigen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Qualigen Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Qualigen Therapeutics backward and forwards among themselves. Qualigen Therapeutics' institutional investor refers to the entity that pools money to purchase Qualigen Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-06-30 | 6.1 K | U.s. Bancorp | 2024-06-30 | 824 | Group One Trading, Lp | 2024-06-30 | 423 | Jpmorgan Chase & Co | 2024-06-30 | 252 | Bank Of America Corp | 2024-06-30 | 52.0 | Signaturefd, Llc | 2024-09-30 | 20.0 | Archer Investment Corporation | 2024-06-30 | 16.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 69.5 K | Hrt Financial Llc | 2024-06-30 | 61.5 K |
Qualigen Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Qualigen Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Qualigen Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Qualigen Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bensler Graydon over two weeks ago Insider Trading | ||
Shishir Sinha over a month ago Acquisition by Shishir Sinha of 100000 shares of Qualigen Therapeutics subject to Rule 16b-3 | ||
Braeden Lichti over a month ago Insider Trading | ||
Kruger Kurt H over two months ago Acquisition by Kruger Kurt H of 40000 shares of Qualigen Therapeutics subject to Rule 16b-3 | ||
Kruger Kurt H over three months ago Acquisition by Kruger Kurt H of 4000 shares of Qualigen Therapeutics at 2.935 subject to Rule 16b-3 | ||
Michael Poirier over six months ago Acquisition by Michael Poirier of 14437 shares of Qualigen Therapeutics at 2.5405 subject to Rule 16b-3 | ||
Ritter Andrew J over a year ago Qualigen Therapeutics exotic insider transaction detected |
Qualigen Therapeutics Outstanding Bonds
Qualigen Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Qualigen Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Qualigen bonds can be classified according to their maturity, which is the date when Qualigen Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| QUALCOMM INC 345 Corp BondUS747525AF05 | View | |
| QUALCOMM INC 48 Corp BondUS747525AK99 | View | |
| QUALCOMM INC 465 Corp BondUS747525AJ27 | View | |
| QUALCOMM INC 325 Corp BondUS747525AU71 | View | |
| QUALCOMM INC 43 Corp BondUS747525AV54 | View | |
| QUALCOMM INCORPORATED Corp BondUS747525BJ18 | View |
Qualigen Therapeutics Corporate Filings
| 22nd of November 2024 Other Reports | ViewVerify | |
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 15th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Pair Trading with Qualigen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Qualigen Stock
| 0.65 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.83 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Qualigen Stock
| 0.83 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.8 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.61 | PHVS | Pharvaris BV | PairCorr |
| 0.43 | LPTX | Leap Therapeutics | PairCorr |
The ability to find closely correlated positions to Qualigen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qualigen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qualigen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qualigen Therapeutics to buy it.
The correlation of Qualigen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Qualigen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Qualigen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Qualigen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.6 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.